A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

- Have histologically confirmed adenocarcinoma of the prostate

- Have disease that is metastatic at the time of the screening as determined by the investigator

- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per milliliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening

- Have progressed on at least 1 novel androgen receptor pathway inhibition (ARPI) but received no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study

- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

- Known history of either brain or leptomeningeal prostate cancer metastases

- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated

- Prior or concurrent second malignancy (other than the disease under study) because the natural history or treatment could interfere with study endpoints

- Received cytotoxic chemotherapy for prostate cancer in any setting

- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies